ASI’s product portfolio includes an extensive range of IVDR compliant cytogenetic imaging and analysis solutions enabling chromosome analysis and karyotyping, digital FISH diagnostics and automated imaging. The company’s proprietary technology provides laboratories with end-to-end solutions from slide scanning and imaging, to quantitative analysis, reporting and LIMS connectivity. HiFISH is ASI’s digital FISH analysis platform that combines automated FISH scanning and capture with real-time analysis for augmented FISH analysis of haematological and solid tumour samples.
The combination of best-in-class products from these two organisations for a complete FISH in vitro diagnostic workflow, will ensure an enhanced experience for end users, enabling them to benefit to the full extent from the expertise and collaboration delivered by this new partnership. The comprehensive workflow delivers on everything from high-quality FISH probes to AI-powered FISH scanning and quantitative analysis resulting in increased throughput and efficiency of FISH analysis.
Speaking about the new commercial partnership, Adrian Smith, CEO of OGT, said: “I’m very excited to be announcing OGT’s new partnership with ASI, whose imaging and analytics can unlock the clinical and diagnostic potential of OGT’s CytoCell FISH probes, including our newly certified IVDR probes. This expanded offering will provide improvements in workflow automation and overall efficiency, enabling faster diagnostic decision making. With the shared goal of advancing genetic clinical care, together we can help to drive the diagnostic capabilities of FISH, and aid clinical decision makers to reach the right diagnosis more often, helping patients to live longer, healthier lives.”
Limor Shiposh, Chief Executive Officer of ASI, commented: “ASI’s imaging and analysis platforms will provide automation, advanced algorithms and image analysis capabilities to realise the full potential of the reliable and easy to use DNA probes.
“ASI is excited to partner with OGT and complete its existing imaging offering with OGT’s unique set of high-quality probes. The combined availability of ASI’s platform and OGT’s CytoCell probes will benefit clinical laboratories, companies and research institutions, enhancing their capabilities to perform comprehensive genomic structural measurements and improve diagnostic accuracy.”